| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9c55cbd632f124625c19c848aaffd9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94336d9a9a79acefc19e0edf9adcadf5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0368
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0276
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2839 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2007-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f96490a01dae4e658888d2902422dc5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f0dfe51887f539c30415025973a6b9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e228f8352bb55df2e6122d0a7d05e97 |
| publicationDate |
2009-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009028853-A1 |
| titleOfInvention |
TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN ALPHAvBETA6 |
| abstract |
The present invention relates to methods of asthma treatment and prevention using α v β 6 antagonists, such as α v β 6 -binding antibodies. In particular, the invention relates to the discovery of a correlation between reduced expression of α v β 6 and the protection from the increase in airway sensitivity seen in chronic allergen-challenged mice. This protection is associated with protection from the usual allergen-induced increase in airway epithelial mast cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111201036-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8992924-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10035859-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10035860-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9745376-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE44681-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8894998-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019081401-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9493566-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8398975-B2 |
| priorityDate |
2006-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |